The treatment modality of CKD-MBD has shifted from single biomarkers (measurement of calcitriol) to serial (economical) measurements of calcium, phosphate, and parathyroid hormone (PTH); these provide a broader insight and better control, helping the management of persons with CKD [46]. Here, PTH is linked to chronic kidney disease.